| Revenue growth | Q2 income ₹457.2 Cr, down 11.4% YoY; H1 ₹1,107.2 Cr, up 35.6%. |
|---|---|
| Margins | EBITDA margin 22.9% vs 30.4% prior year; gross margin 59.4% vs 60.1%. |
| Demand visibility | Strongest RFP activity to date, unquantified; pipeline described as 'steady flow'. |
| Management confidence | Defensive-leaning: repeatedly blames lumpiness; H1 'largely in line' claimed. |
Growth
Q2 income fell 11% YoY to ₹457.2 Cr; H1 rose 36% to ₹1,107.2 Cr. EBITDA margin fell to 22.9% from 30.4%.
Outlook
No quantified FY27 growth; FY28 growth claimed without numbers. Peptide PPQ revenue expected in 6-9 months; capex ~₹1,700-1,800 Cr over three years.
Risks
Lumpy commercial shipments, no launches for 2-3 quarters, working capital at 104 days, input cost and freight pressure, customer concentration, idle peptide capacity costs.
Last quarter's promises, checked
Delivered
- Guided ~20% growth FY27-28 → H1 +35.6% YoY (= BEAT; Q2 -11.4%)
Partly delivered
- Guided pipeline orders 'panning out over next few quarters' → strongest RFP activity, unquantified (= PARTIAL)
Missed
- Guided 25%+ EBITDA margin → Q2 22.9% (= MISS)
- Guided 1 launch in FY27 → none in 2-3 qtrs; next in 1-2 yrs (= MISS)
- Guided further WC gains from Q1 84 days → 104 days (= MISS)
Earnings Call Transcript filed with NSE, NSE: NEULANDLAB. Summary written with AI assistance from the document.
Neuland Laboratories Ltd: key numbers
- Share price
- ₹19,424.00
- Market cap
- ₹24,921 Cr
- Revenue (annual)
- ₹2,023 Cr
- Net profit (annual)
- ₹364.0 Cr
- P/E (TTM)
- 50.1×Sector 47.2×
- Promoter holding
- 32.26%-0.36% QoQ
- FII holding
- 21.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Neuland Laboratories Ltd
All →Neuland Laboratories Investor Presentation: Key Takeaways
Q2FY27 income Rs457.2 Cr (-11.4% YoY), PAT Rs51.1 Cr (-47.0%), EBITDA margin 22.9% on operating deleverage. H1FY27 income Rs1107.2 Cr (+35.6%), PAT Rs198.5 Cr (+80.2%). Capex-led R&D and peptide build-out.
Neuland Laboratories Results Update
Neuland Laboratories' Q2 FY27 standalone revenue fell 11.4% YoY to Rs. 457.2 Crore, with PAT at Rs. 51.1 Crore. The release lacks a full results statement.
Neuland Laboratories Q2 FY27 Results: Net Profit ₹51.6 Cr, Down 46.7% YoY
Neuland Laboratories Ltd reported revenue from operations of ₹449.7 Cr (-12.6% YoY) and net profit of ₹51.6 Cr (-46.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹51.6 Cr · -46.7% YoY
Neuland Laboratories Other Announcement
Neuland Laboratories notified loss of 100 share certificates by shareholder Madan Mohan Singh. The company requested issuance of an entitlement letter in lieu of the lost certificates.
Neuland Laboratories Board Meeting Date
Neuland Laboratories will hold a board meeting on November 3, 2026, to consider and approve the unaudited financial results for the quarter ended September 30, 2026.
Neuland Laboratories Business Update
Neuland Laboratories' Unit 3 manufacturing facility received an Establishment Inspection Report from the US FDA. The agency has officially closed the inspection.